|
|
Article: Optimer Pharmaceuticals Reports First Quarter 2007 Financial Results Including Payment of $20 Million to Par Pharmaceutical to Reacquire the North American Rights to OPT-80.(Financial report)
- Article from:
- Business Wire
- Article date:
- May 10, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced its financial results for the first quarter ended March 31, 2007.
Optimer reported a net loss applicable to common stockholders for the first quarter of 2007 of $24.5 million or, $1.75 per common share. This compares to a net loss applicable to common stockholders in the first quarter of 2006 of $2.1 million, or $0.85 per common share. Results of operations for the first quarter of 2007 had an increase in research and development expenses of $21.3 million primarily due to a $20 million payment to Par Pharmaceutical Companies, Inc. to reacquire the North American rights to OPT-80, formerly ...